Core Laboratories (NYSE:CLB) Stock Price Crosses Above Two Hundred Day Moving Average - Time to Sell?

Key Points

• Core Laboratories Inc. stock price has recently crossed above its 200-day moving average, trading at $12.57, with a peak of $12.68 during Monday's trading.
• A mix of analysts revised their ratings on Core Laboratories, with Zacks and Wall Street Zen upgrading to a "hold" rating, while Stifel Nicolaus lowered the price target from $13.00 to $12.00.
• The company announced a quarterly dividend of $0.01 per share, representing an annualized dividend yield of 0.3%, and has a dividend payout ratio of 6.45%.

Core Laboratories Inc. (NYSE:CLB - Get Free Report)'s stock price passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $12.07 and traded as high as $12.68. Core Laboratories shares last traded at $12.57, with a volume of 360,967 shares trading hands.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on CLB shares. Wall Street Zen raised shares of Core Laboratories from a "sell" rating to a "hold" rating in a research note on Saturday, July 26th. Zacks Research raised shares of Core Laboratories from a "strong sell" rating to a "hold" rating in a research note on Friday, August 15th. Finally, Stifel Nicolaus reduced their price target on shares of Core Laboratories from $13.00 to $12.00 and set a "hold" rating on the stock in a research note on Wednesday, July 16th. Three analysts have rated the stock with a Hold rating, According to data from MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $12.50.

Core Laboratories Stock Performance

The stock has a market cap of $589.31 million, a price-to-earnings ratio of 20.27, a PEG ratio of 3.86 and a beta of 1.46. The company has a current ratio of 2.27, a quick ratio of 1.70 and a debt-to-equity ratio of 0.47. The stock's 50 day moving average is $11.57 and its two-hundred day moving average is $12.07.

Core Laboratories (NYSE:CLB - Get Free Report) last announced its quarterly earnings results on Wednesday, July 23rd. The oil and gas company reported $0.19 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.18 by $0.01. The business had revenue of $130.16 million during the quarter, compared to the consensus estimate of $129.19 million. Core Laboratories had a net margin of 5.73% and a return on equity of 14.15%. The business's revenue was down .3% compared to the same quarter last year. During the same quarter last year, the firm posted $0.22 EPS. Core Laboratories has set its Q3 2025 guidance at 0.180-0.220 EPS. Analysts anticipate that Core Laboratories Inc. will post 0.96 earnings per share for the current fiscal year.

Core Laboratories Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, August 25th. Stockholders of record on Monday, August 4th were paid a dividend of $0.01 per share. The ex-dividend date was Monday, August 4th. This represents a $0.04 dividend on an annualized basis and a dividend yield of 0.3%. Core Laboratories's dividend payout ratio (DPR) is currently 6.45%.

Institutional Trading of Core Laboratories

A number of hedge funds have recently made changes to their positions in the company. Ridgewood Investments LLC raised its stake in shares of Core Laboratories by 2.7% during the first quarter. Ridgewood Investments LLC now owns 33,486 shares of the oil and gas company's stock valued at $502,000 after purchasing an additional 874 shares during the period. The Manufacturers Life Insurance Company raised its stake in shares of Core Laboratories by 6.2% during the second quarter. The Manufacturers Life Insurance Company now owns 17,932 shares of the oil and gas company's stock valued at $207,000 after purchasing an additional 1,040 shares during the period. Mackenzie Financial Corp raised its stake in shares of Core Laboratories by 5.0% during the first quarter. Mackenzie Financial Corp now owns 24,556 shares of the oil and gas company's stock valued at $368,000 after purchasing an additional 1,170 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Core Laboratories by 4.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 27,893 shares of the oil and gas company's stock worth $418,000 after buying an additional 1,170 shares during the last quarter. Finally, Assetmark Inc. increased its stake in shares of Core Laboratories by 92.5% in the first quarter. Assetmark Inc. now owns 2,887 shares of the oil and gas company's stock worth $43,000 after buying an additional 1,387 shares during the last quarter. Hedge funds and other institutional investors own 97.81% of the company's stock.

About Core Laboratories

Core Laboratories Inc provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock and reservoir fluid samples to enhance production and improve recovery of crude oil and gas from its clients' reservoirs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.